Βηματοδότηση της περιοχής του αριστερού σκελικού σκέλους (LBBAP): Τι είναι και ποιες είναι οι νεότερες εξελίξεις στη φυσιολογική βηματοδότηση;

Introduction

Conventional right ventricular pacing (RVP) is unequivocally associated with a 15–20% incidence of pacing-induced cardiomyopathy, a consequence of the resulting electromechanical dyssynchrony. Modern electrophysiology is undergoing a definitive paradigm shift toward conduction system pacing (CSP). This modality directly stimulates the intrinsic cardiac conduction system, with left bundle branch area pacing (LBBAP) currently representing the forefront of this evolution.

What is LBBAP (Left Bundle Branch Area Pacing)?

LBBAP is an innovative, interventricular septal pacing technique. Instead of positioning the lead on the endocardial surface of the right ventricle, it is screwed deeply through the interventricular septum, advancing toward the left side. The objective is to directly capture the left bundle branch of the His bundle or its main fascicles.

Owing to the regional anatomy of the septum, LBBAP demonstrates clear superiority over the older method of His bundle pacing (HBP):

  • Mechanical stability: The thicker septal myocardium provides excellent support and fixation for the lead.
  • Electrical parameters: It ensures remarkably low pacing thresholds and high R-wave sensing, effectively resolving the technical limitations associated with HBP.

Confirming Success in the Electrophysiology Laboratory

The electrophysiologist verifies accurate lead deployment using specific diagnostic criteria:

  1. ECG Morphology: During pacing, a right bundle branch block (RBBB) or incomplete right bundle branch block pattern is observed in lead V1, reflecting the initiation of depolarization from the left ventricle.
  2. Left Ventricular Activation Time (LVAT): A very short and constant LVAT is recorded, measured from the onset of the pacing spike to the R-wave peak in leads V5–V6 (typically <70–80 ms).
  3. Validation of Left Bundle Branch Capture: This is confirmed by an abrupt change in QRS morphology or LVAT during pacing output titration, or by recording a distinct left bundle branch (LBB) potential on the intracardiac electrogram.

Updates in Clinical Management and Guidelines

The clinical maturity of this method has triggered major shifts in standard practice:

  • The LECART Trial [1]: This randomized controlled trial directly compared cardiac resynchronization therapy (CRT) via conventional biventricular (BiV) pacing against LBBAP in heart failure patients presenting with left bundle branch block (LBBB). LBBAP achieved significantly greater QRS narrowing, shorter procedural duration, and a striking reduction in surgical lead revisions (merely 2% compared to 15% in the BiV arm).
  • ESC/EHRA Clinical Consensus Statement [2]: Recent clinical guidelines establish LBBAP as a preferred strategy (rather than a secondary alternative) for patients with a reduced ejection fraction (LVEF ≤40%) and an anticipated high ventricular pacing burden (>40%), aiming to prevent the onset of pacing-induced heart failure.
  • FDA Approval of OmniaSecure™ for LBBAP (March 2026): The FDA granted a milestone expanded indication for the OmniaSecure™ defibrillation lead, designating it as the first and only defibrillator lead globally indicated for left bundle branch area (LBB area) placement to deliver conduction system pacing.

Conclusion

LBBAP has transitioned from a backup "bailout" solution to the new standard of care in cardiac pacing. Its capability to safely and reliably preserve or restore optimal physiological electromechanical synchrony of the left ventricle radically redefines the clinical trajectory of patients requiring pacing or cardiac resynchronization therapy.

References

  1. Grieten L. Left bundle branch area pacing versus biventricular pacing for cardiac resynchronization therapy: the LECART trial. Presented at: European Heart Rhythm Association (EHRA) Congress; April 12-14, 2026; Paris, France.
  2. Burri H, Jastrzebski M, Cano Ó, Čurila K, de Pooter J, Huang W, Israel C, Joza J, Romero J, Vernooy K, Vijayaraman P, Whinnett Z, Zanon F. EHRA clinical consensus statement on conduction system pacing implantation: endorsed by the Asia Pacific Heart Rhythm Society (APHRS), Canadian Heart Rhythm Society (CHRS), and Latin American Heart Rhythm Society (LAHRS). Europace. 2023 Apr 15;25(4):1208-1236. doi: 10.1093/europace/euad043. Erratum in: Europace. 2023 Apr 15;25(4):1520. doi: 10.1093/europace/euad098. PMID: 37061848; PMCID: PMC10105878.

References

  1. Grieten L. Left bundle branch area pacing versus biventricular pacing for cardiac resynchronization therapy: the LECART trial. Presented at: European Heart Rhythm Association (EHRA) Congress; April 12-14, 2026; Paris, France.
  2. Burri H, Jastrzebski M, Cano Ó, Čurila K, de Pooter J, Huang W, Israel C, Joza J, Romero J, Vernooy K, Vijayaraman P, Whinnett Z, Zanon F. EHRA clinical consensus statement on conduction system pacing implantation: endorsed by the Asia Pacific Heart Rhythm Society (APHRS), Canadian Heart Rhythm Society (CHRS), and Latin American Heart Rhythm Society (LAHRS). Europace. 2023 Apr 15;25(4):1208-1236. doi: 10.1093/europace/euad043. Erratum in: Europace. 2023 Apr 15;25(4):1520. doi: 10.1093/europace/euad098. PMID: 37061848; PMCID: PMC10105878.
2026-11-18T23:21:25+00:00